Responses

Download PDFPDF

Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies
Free
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Autologous serum in epithelial defects: Authors' reply
    • John Dart, MA DM FRCS
    • Other Contributors:
      • A Poon

    Dear Editor

    Vajpayee and colleagues have criticised several aspects of our study and justified their views with unrepresentative quotations from the literature.

    Choice of time period before an epithelial defect can be described as "persistent".
    There is no accepted definition of persistent epithelial defect (PED) that includes a time period. We favour the definition given in one text"......

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Role of autologous serum in persistent epithelial defects

    Dear Editor

    Poon et al.[1] in their excellent article have reiterated the efficacy of autologous serum in the treatment of persistent epithelial defects (PEDs) of the cornea. We would like to invite the attention of the authors to certain aspects of the study. The authors have considered a period of one week for labeling an epithelial defect to be persistent. However, most studies on a similar subject have tak...

    Show More
    Conflict of Interest:
    None declared.